Novikova, Gloriia http://orcid.org/0000-0002-3916-2627
Kapoor, Manav
TCW, Julia http://orcid.org/0000-0002-3054-9374
Abud, Edsel M.
Efthymiou, Anastasia G.
Chen, Steven X. http://orcid.org/0000-0003-3463-5824
Cheng, Haoxiang http://orcid.org/0000-0002-1393-6006
Fullard, John F.
Bendl, Jaroslav http://orcid.org/0000-0001-9989-2720
Liu, Yiyuan
Roussos, Panos http://orcid.org/0000-0002-4640-6239
Björkegren, Johan LM http://orcid.org/0000-0003-1945-7425
Liu, Yunlong
Poon, Wayne W. http://orcid.org/0000-0003-0625-3968
Hao, Ke http://orcid.org/0000-0002-1815-9197
Marcora, Edoardo http://orcid.org/0000-0002-3829-4927
Goate, Alison M. http://orcid.org/0000-0002-0576-2472
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Aging (K01AG062683, F31 AG059337-01, R01AG050986)
U.S. Department of Health & Human Services | NIH | National Institute on Aging
U.S. Department of Health & Human Services | NIH | National Institute on Aging
Article History
Received: 16 September 2020
Accepted: 10 February 2021
First Online: 12 March 2021
Competing interests
: A.M.G. has consulted for Eisai, Biogen, Pfizer, AbbVie, Cognition Therapeutics and GSK. She also served on the SAB at Denali Therapeutics from 2015 to 2018. This work was funded by grants from the NIH: U01AG052411 (A.M.G.), RF1AG054011 (A.M.G.), U01AG058635 (A.M.G.), NIA K01AG062683 (J.TCW.), AG016573 (W.W.P.), F31 AG059337-01 (A.G.E.), R01AG050986 (P.R.), 1R01ES029212-01 (K.H.), R01HL125863 (J.L.M.B.), American Heart Association (J.L.M.B.), the Swedish Research Council (J.L.M.B.), Heart Lung Foundation (J.L.M.B.), and by Astra-Zeneca through ICMC, Karolinska Institutet (J.L.M.B.), The JPB Foundation, The Robert and Renee Belfer Foundation. E.M.A. and W.W.P. are named co-inventors of patent WO/2018/160496 related to the differentiation and use of human pluripotent stem cells and hematopoietic progenitors into microglia. K.H. receives financial compensation from Sema4 (an Icahn School of Medicine at Mount Sinai spin-off company). Sema4 is currently majority owned by the Icahn School of Medicine at Mount Sinai. The remaining authors declare no competing interests.